Article Details
Retrieved on: 2024-04-17 19:11:54
Tags for this article:
Click the tags to see associated articles and topics
Summary
Truist Securities maintains its Buy rating on Tourmaline Bio despite a 60% stock drop, citing confidence in their biotech product TOUR006 compared to Roche's satralizumab, while noting Tourmaline's strong market liquidity and financial health.
Article found on: www.investing.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here